Olufunmilayo I. Olopade
Affiliations: | Cancer Biology | University of Chicago, Chicago, IL |
Area:
Genetics, Molecular Biology, OncologyGoogle:
"Olufunmilayo Olopade"Children
Sign in to add trainee| Johnnie L. Byrd | grad student | 2008 | Chicago |
| Brooke E. Sylvester | grad student | 2011 | Chicago |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Barnes DR, Tyrer JP, Dennis J, et al. (2024) Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk. Medrxiv : the Preprint Server For Health Sciences |
| Lubinski J, Kotsopoulos J, Moller P, et al. (2024) MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations. Jama Oncology |
| Freeman JQ, Sheade JB, Zhao F, et al. (2024) Racial differences in familiarity, interest, and use of integrative medicine among patients with breast cancer. Research Square |
| Ochs-Balcom HM, Preus L, Du Z, et al. (2024) Novel breast cancer susceptibility loci under linkage peaks identified in African ancestry consortia. Human Molecular Genetics |
| Madorsky Rowdo FP, Xiao G, Khramtsova GF, et al. (2024) Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Letters. 216608 |
| Omoleye OJ, Freeman JQ, Oluwasanu M, et al. (2024) Benign breast disease and breast cancer risk in African women: a case-control study. Cancer Causes & Control : Ccc |
| Kyalwazi B, Yau C, Campbell MJ, et al. (2023) Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer. Jama Network Open. 6: e2349646 |
| Vannier AGL, Dhungana A, Zhao F, et al. (2023) Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer |
| Rowdo FPM, Xiao G, Khramtsova GF, et al. (2023) Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Biorxiv : the Preprint Server For Biology |
| Metcalfe K, Huzarski T, Gronwald J, et al. (2023) Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis. British Journal of Cancer |